Area Editoriale
Background and Aim To test whetherthe chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, hadless Helicobacter pylori-related intestinal metaplasia or if such users' intestinalmetaplasia could be prone to disappear after H. pylori eradication. Methods Thestudy enrolled 150 chronic celecoxib users and 216 non-users who underwentpan-endoscopy to detect H. pylori infection and its related intestinalmetaplasia. One hundred and three H. pylori-infected patients with intestinalmetaplasia (43 chronic celecoxib users and 60 non-users) received anti-H.pylori therapy and completed the 12-month follow-up to survey the regression ofintestinal metaplasia by mean intestinal metaplasia score. Results There wereno differences in the prevalence of H. pylori-related intestinal metaplasiabetween the chronic celecoxib users and controls (P > 0.05). On the 12thmonth of follow-up, chronic celecoxib users had a lower mean intestinal metaplasiascore (1.2 vs. 1.8, P < 0.005) and a higher regression rate of intestinalmetaplasia (42% vs. 20%, P = 0.027) than non-users. Conclusions With H. pyloriinfection, chronic celecoxib users still showed limited effects to decreaseintestinal metaplasia. Nevertheless, celecoxib should be promising to assist H.pylori eradication for the control of gastric intestinal metaplasia and cancerrisk.Leggi l'articolo